Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Here's what most people miss: it needs physical activity to do its job
In a phase 2, multicenter, randomized, placebo controlled double blind study, crizanlizumab with or without hydroxyurea (SUSTAIN study) (ClinicalTrails.gov Identifier: NCT01895361) showed that patients on the treatment arm had significantly lower rate of sickle-related pain crises compared to placebo with a lower incidence of adverse events - 10% of patients suffered from moderate side effects while one patient suffered from an intracranial bleed during treatment with this drug that could also interfere with platelet function via its effects on selectins ( Post hoc analyses showed that more patients were VOC event-free in the crizanlizumab arm than in the placebo arm, and that crizanlizumab also significantly increased time-to-first VOC compared to the placebo (Kutlar et al., 2019)
[DOI] [PubMed] [Google Scholar] 16.Kim HJ, Kim BH, Han YS, Yang I, Kim KJ, Dong SH, et al
The spatial transcriptomics dataset of HCCDB includes 17 tissue sections from 5 patients, covering immune, tumor, adjacent, and stromal regions
